Clinical Trial Update: Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating adjuvant therapy tailored by residual circulating tumor DNA in patients with HPV-positive oropharyngeal squamous cell carcinom…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer
• Head and Neck Squamous Cell Carcinoma
• Hpv-positive Oropharyngeal Squamous Cell Carcinoma
• Oropharyngeal Cancer
• Oropharyngeal Squamous Cell Carcinoma

Snippet

Sponsor: University of Maryland, Baltimore | Conditions: Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma | Phase 2 | Status: RECRUITING